Dyne Therapeutics (DYN) just unveiled an update.
Dyne Therapeutics, Inc. has appointed John Cox, a seasoned biotech leader, as its new President and CEO, also welcoming him to the Board of Directors. Cox, with a rich industry background including executive roles at Repertoire Immune Medicines and Bioverativ, will receive a $700,000 base salary and eligibility for significant annual bonuses and stock options. His transition comes with a comprehensive severance package and inducement plan, ensuring a robust incentive structure and potential severance benefits. Meanwhile, the outgoing CEO, Joshua Brumm, has transitioned to a consulting role with a corresponding separation agreement.
Find detailed analytics on DYN stock on TipRanks’ Stock Analysis page.
